Technology Prognosis

tracking technologies before you have to make a decision

Bevyxxa (Betrixaban)

March 29, 2018

Bevyxxa is a potent and specific inhibitor of human factor Xa activity that acts by competitively binding to the active site of factor Xa, preventing its ability to convert prothrombin to thrombin. It is the first non-vitamin K antagonist oral anticoagulant (NOAC) approved by the FDA for venous thromboembolism (VTE) prophylaxis in hospitalized acute medically ill adult patients who are at risk for thromboembolic complications.